This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): intranasal morphine, intranasal MNS075
Description: Rylomine is an intranasal formulation of morphine, an opioid agonist, for rapid delivery.
Deal Structure: In August 2000, IDDS (now Javelin) entered into a license agreement, which was amended in October2001 and October 2003, with West Pharmaceutical under which IDDS acquired a worldwide, exclusive right to develop and commercialize intranasal morphine under patents held by West Pharmaceutical for the transmucosal delivery of morphine to humans and animals for the treatment of pain. The licensed patent portfolio from West Pharmaceutical provides U.S. protection until 2014 and worldwide protection through 2016. The term of the license remains in effect until the last to expire of the Licensed Patents (as defined in the license agreement). (IDDS also filed patent applications to expand the life of these patents.) IDDS is required to pay West Pharmaceutical an aggregate of up to $5.0 million for research and development milestones if certain defined events occur, which include the first filing of a marketing authorization application with a regulatory agency, first approval of a marketing...See full deal structure in Biomedtracker
Pink Sheet Javelin Rylomine pivotal trial
Additional information available to subscribers only: